The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Discover a recent study that revealed that patients treated for prostate cancer, particularly with radiotherapy, have an ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.

Prostate cancer patients may have long-term complications from treatment ... Nov. 7 (UPI) -- The U.S. Food and Drug ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

is a recently developed imaging test used for people with prostate cancer. It looks for a protein called prostate-specific membrane antigen, which is produced by most, but not all, prostate cancers.

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...